跳到主要內容區
:::

資訊分類清單

:::
  1. 首頁

張俊彥 Jang-Yang Chang

Jang-Yang,Chang

張俊彥  國立成功大學醫學院 院長 / 國家衛生研究院癌症研究所 特聘研究員級主治醫師 (Jang-Yang Chang)

E-mail：z10208083@email.ncku.edu.tw

電話：06-2353535 分機5000 

傳真：06-2353660

　

學經歷

　

學歷

 國防醫學院醫學士
　 　 　
　 現職 國立成功大學醫學院 院長
　 　 國家衛生研究院癌症研究所特聘研究員級主治醫師
　 　 　
　 經歷 2013~ 國立成功大學醫學院 院長
　 　 2008/09 國家衛生研究院癌症研究所特聘研究員
　 　 2008/01 國家衛生研究院癌症研究所主任
　 　 2007/08 成大醫院血液腫瘤科主治醫師
　 　 2006/01~ 國家衛生研究院癌症研究所副主任
　 　 2004/6-2008 Chairman, Safety and Data Monitoring committee, TCOG, Taiwan
　 　 2004/04 國家衛生研究院癌症研究所調查員
　 　 2003-2005 中華腫瘤學會常務理事
　 　 2003/08 國防醫學院內科兼任教授
　 　 2001 中華腫瘤學會董事會成員
　 　 2000/9-2004/3 國家衛生研究院癌症研究所助理研究員
　 　 1999 董事會成員Sino-American Cancer Foundatio,Taiwan
　 　 1997 國家衛生研究院癌症研究所資深主治醫師
　 　 1997 Chief, Hematology / Oncology, Cheng-Hsien Medical Center, Taiwan
　 　 1997-2006 台大醫院腫瘤科兼任主治醫師
　 　 1997-2001 中華腫瘤學會秘書長
　 　 1994-2003/7 國防醫學院內科副教授
　 　 1994-1996 骨髓移植學會董事會成員
　 　 1993 三軍總醫院腫瘤科科長
　 　 1991-1992 Attending physician, Medical Mission in Republic of Central Africa
　 　 1989-1991 耶魯大學醫學院藥理學系訪問學者
　 　 1987 三軍總醫院血液腫瘤科主治醫師
　 　 1987-1989 Fellow of Medical Oncology Training Program, Institute of Biomedical Science, Academia Sinica, Taiwan
　 　 1986-1987 三軍總醫院血液腫瘤科住院醫師
　 　 1982-1986 Resident, 三軍總醫院
　 　 1981-1982 Internship training, 三軍總醫院

　

專長/研究興趣

　

Medical Oncology, Cancer pharmacology and drug discovery

　

Dr. Chang's research interests focus on three fields; (1) study the mechanisms of drug resistance, especially camptothecins, and the relationship between CPT-resistance and DNA repair; (2) anti-cancer drug development, focusing on topoisomerase I and II and tubulin inhibitors; (3) regulation of DNA repair enzyme, MGMT.

　

 　
　 主要研究方向
　

  1. Development of anticancer drugs

  2. Study the mechanisms of anticancer drug resistance.
　 　
　 研究項目：
　
臨床研究：

  1. A phase III study of postoperative adjuvant chemoradiotherapy for patients with stage III and IVb stomach cancer. (PI)

  2. A phase II study of gemcitabine and vinorelbine in cisplatin-resistant nasopharyngeal carcinoma patients. (co-PI)

  3. A phase I study of PI-88 in advanced malignancies. (co-PI)

  4. A phase I and PK study of thalidomide in hepatocellular carcinoma. (co-PI)

  5. A phase II study of weekly CPT-11 in recurrent NPC. (PI)

  6. A phase II study of weekly oxaliplatin plus HDFL in patients with advanced gastric cancer (co-PI)

  7. A phse II study of taxol, UFT and leucovorin in patients with advanced gastric cancer. (co-PI)

  8. A phase I/II study of docetaxel, cisplatin and HDFL in patients with advanced gastric cancer. (PI)

  9. A phase III study of thalidomide in patients with poor liver function hepatocellular carcinoma. (co-PI)

  10. Phase I and PK studies of PEP02 in patients with advanced malignancies. (PI)

  11. Phase I study of PEP02 with HDFL in patients with advanced malignancies. (co-PI)

  12. Phase I and PK study of biweekly PEP02 in patients with advanced colorectal cancer (PI).
　
基礎研究：

  1. Study the distribution of somatostatin receptor in human cancer tissue.

  2. Study the mechanism of CPT resistance in human nasopharyngeal cancer cells.

  3. Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation.

  4. Synthesis and structure-activity relationships of new AHMA derivatives as topoisomerase-II mediated antitumor agents.

  5. Study the indole derivatives as antitumor agents.

  6. Study the mechanims of action of BPR0Y007, a novel anticancer agent.

  7. Study the role of O6-MGMT in determining the cytotoxicty of topoisomerase I inhibitors.

  8. Transcriptional inhibition of O6MGMT gene of topoisomerase I inhibitors.

  9. Isolation the putative transporter responsible for resistance to topoisomerase I inhibitors in a vincristine-resistant cell line.

  10. Study the mechanism of action of a potential antitumor agent isolated from a herb medicine.

  11. Study the interaction of arsenic trioxide with antitumor agents.

  12. Study the interaction of new topoisomerase I inhibitor, DB67, with other antitumor agents.

  13. Study the pathway of BPR0Y007-induced apoptosis.

  14. Study on the regulation of DNA repair enzyme, MGMT, in human cancer cells.

  15. Study on the development of anti-tubulin compounds
　

榮譽獎項
　
　 2010 Outstanding Poster Award, The 15th Annual Taiwan Joint Cancer Conference, 2010
　 2008 Outstanding Poster Award, The 13rd Annual Taiwan Joint Cancer Conference
　 2007 Outstanding Poster Award, The 12nd Annual Taiwan Joint Cancer Conference
　 2006 Outstanding Poster Award, The 11th Annual Taiwan Joint Cancer Conference
　 2005 徐千田防癌研究基金癌症傑出研究獎 (基礎組)
　 2005 Outstanding Poster Award, The 10th Annual Taiwan Joint Cancer Conference
　 2004 Outstanding Poster award, The 9th Annual Taiwan Joint Cancer Conference
　 2003 Outstanding Poster award, The 8th Annual Taiwan Joint Cancer Conference
　 2001 Outstanding Poster award, The 6th Annual Taiwan Joint Cancer Conference
 
　

 研究成果 (Publications) -- Jang-Yang Chang
　

(A) Research Articles

  1. Chang CY, Chuang HY, Lee HY, Yeh TK, Kuo CC, Chang CY, Chang JY*, Liou JP. Antimitotic and vascular disrupting agents: 2-Hydroxy-3,4,5-trimethoxybenzophenones. Eur J Med Chem ;77C:306-314, 2014 Apr 22.

  2. Huang CC, Chen KL, Cheung CH, Chang JY*. Autophagy induced by cathepsin S inhibition induces early ROS production, oxidative DNA damage, and cell death via xanthine oxidase. Free Radic Biol Med ;65:1473-86, 2013 Dec

  3. Lee HY, Pan SL, Su MC, Liu YM, Kuo CC, Chang YT, Wu JS, Nien CY, Mehndiratta S, Chang CY, Wu SY, Lai MJ, Chang JY*, Liou JP. Furanylazaindoles: potent anticancer agents in vitro and in vivo. J Med Chem ;56(20):8008-18, 2013 Oct 24

  4. Lee WH, Liu HE, Chang JY*, Liou JP, Huang HM. MPT0B169, a new tubulin inhibitor, inhibits cell growth and induces G2/M arrest in nonresistant and paclitaxel-resistant cancer cells. Pharmacology ;92(1-2):90-8, 2013

  5. Cheng YC, Liou JP, Kuo CC, Lai WY, Shih KH, Chang CY, Pan WY, Tseng JT, Chang JY*. MPT0B098, a novel microtubule

     inhibitor that destabilizes the hypoxia-inducible factor-1α mRNA through decreasing nuclear-cytoplasmic translocation of RNA-

    binding protein HuR. Mol Cancer Ther ;12(7):1202-12, 2013 Jul

  6.  Chiang NJ, Lin CI, Liou JP, Kuo CC, Chang CY, Chen LT, Chang JY*. A novel synthetic microtubule inhibitor, MPT0B214

     exhibits antitumor activity in human tumor cells through mitochondria-dependent intrinsic pathway. PLoS One ;8(3):e58953,

     2013.

  7. Chou, L.-H., Lin, P.-C, Chang J.-S,, Chu, P.-Y., Lee, P.-K., Chen, S.-N., Cheng, Y.-M., Lee, J.-C., Chang, J.-Y., and Liu, T.-W*. Differences in frequencies of K-ras c12-13 genotypes by gender and pathological phenotypes in colorectal tumor measured using the allele discrimination method. Environmental and Molecular Mutagenesis. 53(1): 22-31, 2012

  8. Shih, Y.-T, Wang, M.-C, Peng, H,-H, Chen, T,-F, Chang, J.-Y and Chiu JJ. Modulation of chemotactic and pro-inflammatory activities of endothelial progenitor cells by hepatocellular carcinoma. Cellular Signalling 24: 779-793, 2012

  9. Lee, H.-Y#, Chang, J.-Y#., Nien, C.-Y., Kuo, C.-C., Lai, W.-Y., Chang, C.-Y., and Liou, J.-P. 5-amino-2-aroylquinolones as highly potent tubulin polymerization inhibitors. Part 2 the impact of bridging groups at C2 position. J Med Chem. 22: 54(24): 8517-25,2011 (# equally contributed)

  10. Hsieh CL, Tseng MH, Pan RN, Chang JY, Kuo CC, Lee TH and Kuo YH. Novel terpenoids from Calocerus macrolepis var. formosana. Chem Biodivers. 8(10): 1901-7, 2011

  11. Chang, K.-Y., Tsai, S.-Y., Wu, C.-M., Yen, C.-Y., Chuang, B.-F., and Chang, J.-Y*. Novel PI3K/mTOR inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clinical Cancer Research, 7116-7126, 2011

  12. Cheung CHA, Cheng LT, Chang KY, Chen HH and Chang JY*. Investigations of the inhibitor-of-apoptosis protein (IAP), Survivin: the past, present and future. Frontiers in Bioscience, 16:952-961, 2011.

  13. Hsieh, C.-L., Tseng, M.-H., Pan, R.-N., Chang, J.-Y., Kuo, C.-C., Lee, T.-H., Kuo, Y.-H.* Labdanecaryophyllic acid, a novel cytotoxic C35 terpenoid from Calocedrus macrolepis var. formosana. Tetrahedron Letters 52(4):515-517, 2011.

  14. Chuang, H.-Y., Chang, JY (co-first author), Lai, M.-J., Kuo, C.-C., Lee, H.-Y., Hsieh, H.-P., Chen, Y.-J., Chen, L.-T., Pan, W.-Y., Liou, J.-P. 2-amino-3,4,5-trimethoxybenzophenones as potent tubulin polymerization inhibitors. ChemMedChem 6: 450-456, 2011.

  15. Hsieh CC, Lee HY, Nein CY, Kuo CC, Chang CY, Chang JY* and Liu JP*. Synthesis and biological evaluation of 4-aroyl-6,7,8-trimethoxyquinones as a novel class of anticancer agent. Molecules 16 (3): 2274-2284, 2011.

  16. Hu CB, Chen CP, Yeh TK, Song JS, Chang CY, Chuu JJ, Tung FF, Hwang LL, Ho PY, Chen TY, Lin CH, Wang MH, Chang KY, Huang CL, Lin HL, Li WT, Huang DR, Chern JH, Chang JY, Chao YS and Chen CT. BPR0C261 is a novel orally active antitumor agent with antimitotic and antiangiogenic activities. Cancer Science 102 (1): 182-191, 2011.

  17. Cheung CHA, Coumar MS, Chang JY* and Hsieh HP*. Aurora kinase inhibitors patents and agents in clinical testing: an update (2009-2010). Experts Opinion on Therapeutic Patents 21 (6): 1-28, 2011 (invited review).

  18. Lee HY, Chang JY (Co-first author), Chang LY, Lai WY, Lai MJ, Shih KH, Kuo CC, Chang CY and Liu JY. Concise syntheses of N-aryl-trimethoxyindoles as antimitotic and vascular disrupting agents: application of copper-mediated Ullmann type arylation. Organic and Biomolecular Chemistry 9(9):3154-3157, 2011.

  19. Tung YS, Morhan C, Wu YS, Shiao HY, Chang JY, Liu JP, Paritosh S, Chang JW, Chang CY, Kuo CC, Yeh TK, Lin CY, Wu JS, Wu SY, Liao CC and Hiseh HP. Scaffod-hopping strategy: Synthesis and biological evaluation of 5,6-fused bicyclic-heteroaromatics to identify orally-bioavailable anticancer agents. J Med Chem. 54:3076-80, 2011.

  20. Ch’ang HJ, Lin YL, Wang HP, Chiu YF, Chang MC, Hsiu CH, Tien YW, Chen JS, Hiseh RK, Lin BW, Shan YS, Cheng AL, Chang JY, Whang-Peng J, Hwang TL and Chen LT. Induction chemotherapy with gemcitabine, oxaliplatin, 5-FU/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan Cooperative Oncology group phase II study. Int. J of Radiation Oncology, Biology, Physics. 2011 Mar 21 [Epub ahead of print].

  21. Charoenfuprasert S, Yang YY, Lu YC, Chao KC, Chu PY, Lai CR, Hsu KF, Chang KC, Chen YC, Chen LT, Chang JY, Leu SJ and Shih NY. Identification of salt-inducible kinase 3 as novel tumor antigen associated with tumorigenesis of ovarian cancer. Oncogene 2011 Mar 14 [Epub ahead of print].

  22. Lai, M.-J., Chang, J.-Y. (Co-first author), Lee, H.-Y., Kuo, C.-C., Lin, M.-H., Hsieh, H.-P., Chang, C.-Y., Wu, J.-S., Wu, S.-Y., Shey, K.-S., Liou, J.-P.* Synthesis and biological evaluation of 1-(4’-indolyl and 6’-quinolinyl)indoles as a new class of potent anticancer agents. European Journal of Medicinal Chemistry 2011 (In press)

  23. Chen, H.-H., Chiang, W., Chang, J.-Y., Chien, Y.-L., Lee, C.-K., Liu, K.-J., Cheng, Y.-T., Chen, T.-F., Kuo, Y.-H., Kuo, C.-C.* Antimutagenic Constituents of Adlay (Coix lachryma-jobi L. var. ma-yuen Stapf) with Potential Cancer Chemopreventive Activity. Journal of Agricultural and Food Chemistry 2011 (In press)

  24. Kuo, C.-C., Liu, T.-W., Chen, L.-T., Shiah, H.-S., Wu, C.-M., Cheng, Y.-T., Pan, W.-Y., Liu, J.-F., Chen, K.-L., Yang, Y.-N., Chen, S.-N., Chang, J.-Y.* Combination of Arsenic Trioxide and BCNU Synergistically Triggers Redox–mediated Autophagic Cell Death in Human Solid Tumors. Free Radical Biology and Medicine, 51: 2195-2209, 2011

  25. Yang, Y.-N., Chou, K.-M., Pan, W.-Y., Chen, Y.-W., Tsou, T.-C., Yeh, S.-C., Cheung, C.-H.A., Chen, L.-T., Chang, J.-Y*. Enhancement of Non-homologous End Joining DNA Repair Capacity Confers Cancer Cells Resistance to the Novel Selenophene Compound, D-501036. Cancer Letters, 2011 (revised)

  26. TK Yeh, CM Li, CP Chen, CL Huang, HS Wang, CJ Shen, CY Chang, CM Chang, YS Chao, CT Lin, Chang JY*, and CT Chen*. Comparative Antitumor Activities and Pharmacokinetics of Silatecans DB-67 and DB-91. Pharmacological Research, 61: 108-115, 2010.

  27. Hsieh CC, Kuo YH, Kuo CC, Chen LT, Cheung AC, Chao TY, Lin CH, Chang CY, Pan WY, Chen SC, Chen TW, Lung CC and Chang JY*. Chamacypanone C, a novel skeleton microtubule inhibitor, with anticancer activity by trigger caspase 8-Fas/FasL dependent apoptotic pathway in human cancer cells. Biochemical Pharmacology, 79: 1261-1271, 2010.

  28. Nien CY, Chen YC, Kuo CC, Hsieh HP, Chang CY, Hsu KY, Liou JP* and Chang JY*. 5-amino-2-aroylquinolones as highly potent tubulin polymerization inhibitors. J Med Chem, 53:2309-13, 2010.

  29. Kanwar RK, Cheung CHA, Chang JY and Jagat R. Kanwar. Recent advances in anti-survivin treatment for cancer. Current Medicinal Chemistry. 17(15): 1509-15, 2010.

  30. Wang YU, Tsai YS, Huang JL, Ka-Wo Lee KW, Kuo CC, Wang CS, A-Mei Huang AM, Chang JY, Jong YJ, and Chang-Shen Lin CS. Arecoline arrests cells at prometaphase by deregulating mitotic spindle assembly and spindle assembly checkpoint: implication for carcinogenesis. Oral Oncology, 46(4): 255-262, 2010.

  31. Cheung CHA, Chen HH, Cheng LT, Lyu KW, Kanwar JR and Chang JY*. Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells. Molecular Cancer, 15: 9(1): 77, 2010.

  32. Chang JY, Lai, MJ, Chang YT, Lee HY, Chen YC, Kuo CC, Su MC, Chang CY and Liu JP. Synthesis and biological evaluation of 7-arylindoline-1-benzenesulphonamides as a novel class of potent anticancer agents. Med Chem Comm 1: 152-155, 2010.

  33. Chen JC, Uang BJ, Lyu PC, Chang JY, Liu KJ, Kuo CC, Hsieh HP, Wang HC, Cheng CS, Chang YH, Chang MTD, Chang WHW, and Chun-Cheng Lin. Design and synthesize of α-ketoamides as cathepsin S inhibitors with potential applications against tumor invasion and angiogenesis. J Med Chem, 53(11): 4545-9, 2010.

  34. Chen CC, Wu JH., Yang NS, Chang, JY, Kuo CC., Wang SY., Kuo YH.* A Cytotoxic C35 Terpenoid Cryptotrione from the Bark of Cryptomeria japonica. Organic Letters 12(12): 2785-2789, 2010.

  35. Wu YY, Chang JY and Chao TY. Paclitaxel and carboplatin-induced complete remission in patients with peritoneal carcinomatosis of unknown origin: a report of two cases and review of literature. Tumori. 96(2): 336-9, 2010.

  36. Lung JH, Liu KJ, Chang JY, Leu SS and Shih NY. MBP-1 is efficiently encoded by an alternative transcript of ENO-1 gene but post-translationally regulated by proteosome-dependent protein turnover. FEBS J, 277(20):4308-21, 2010.

  37. Cheung CHA, Cheng LT, Chang KY, Chen HH and Chang JY*. Investigations of the inhibitor-of-apoptosis protein (IAP), Survivin: the past, present and future. Frontiers in Bioscience, PLoSOne 5(9): e12564, 2010.

  38. Huang WL, Yeh HH, Lin CC, Lai WW, Chang JY, Chang WT and Su WC. Signal transducer and activator of transcription 3 up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and isolated human cancer cells. Molecular Cancer 9:309, 2010.

  39. Mohane HC, Cheung CHA, Chang JY and Hsieh HP*. Advances in aurora kinase inhibitors patents. Experts Opinion on Therapeutic Patents 19 (3): 321-356, 2009 (Invited Review).

  40. Lai MJ, Kuo CC, Yeh TK, Hsieh HP, Pan WY, Hsu KY, Chang JY*,and Liou JP*. Discovery of 1-Benzyl-4,5,6-Trimethoxyindoles as a Novel Class of Potent Antimitotic Agents. ChemmedChem, Apr;4(4):588-93, 2009.

  41. Cheung CHA, Coumar MC, Hsieh HP* and Chang JY*. Aurora kinase inhibitors in preclinical/clinical testing. Experts Opinion on Investigation Drugs, 18 (4): 379-398, 2009 (Invited Review).

  42. Chang KY, Chang JY and Yen Y. Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis.- JNCCN, 7(4):423-7, 2009.

  43. Chaing YK, Kuo CC, Chen CT, Coumar MS, Hsieh HP, Chang CY, Jseng HY, Wu MH, Wu JS, Leou JS, Song JS, Chang JY, Lyu PC, Chao YS and Wu SY. Generation of ligand-based pharmacophore model and virtual screening for identification of novel anti-tubulin inhibitors with potent anticancer activity. J Med Chem. 52(14): 4221-33, 2009.

  44. Chen LT, Shiah HS, Chao Y, Chang JY, Chen LT and Whang-Peng J. Alpha-fetoprotein response in advanced HCC receiving cytostatic treatment. JCO, 2009 Dec 20;27(36):e271.

  45. Wu YS#, Coumar MS#, Chang JY#, Sun HY, Kuo FM, Kuo CC, Chen YJ, Chen CY, Liao JY, Chen CP, Yao HT, Chiang YK, Tau UK, Chen CT, Wu SY, Yeh TK and Hsieh HP. Synthesize and evaluation of 3-aroulindoles as anticancer agent: metabolic approach. J Med Chem. 4941-4945, 2009.(# equal contribution).

  46. Cheung CHA, Chen HH, Kuo CC, Chang CY, Coumar MS, Hsieh HP and Chang JY*. Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Molecular Cancer 8 (1): 43, 2009.

  47. Kao YH, Hsieh HP, Chitlimalla SK, Kuo CC, Hsu KS, Chang CY, Liu CF, Tsu YC, Chuang SE and Chang JY* BPR1H0101, a novel synthetic indole-based peroxisome proliferators-activated receptor a/r agonist, inhibits topoisomerase II catalytic activity. Anti-Cancer Drugs Feb;19(2):151-158, 2008 (NSC 95-2752-B-400-001-PAE) SCI:2.245.

  48. Ma LC, Kuo CC, Liu JF, Chen LT and Chang JY*. Transcriptional repression of O6-methylguanine methytransferase gene rendering cells hypersentitive to N,N'-BIS(2-chloroethyl)-N-nitrosurea in camptothecin-resistant cells. Mol. Pharm. 74(2): 517-26, 2008 (Fastforward online publication, May 20, 2008).

  49. Liou JP, Wu CY, Kuo CC, Chang CY, Chen CM, Hsieh SP* and Chang JY*. Discovery of 4-amino- and 4-hydroxy-1-aroyindoles as potent tubulin polymerization inhibitors. J Med Chem, 24; 51(14): 4351-4355, 2008.

  50. Chen YW, Cleaver J, Hatabet Z, Honkanen R, Chang JY, Yen Y and Chou KM. Human Polymerase η (eta) activity and translocation is regulated by phosphorylation. PNAS, 105 (43): 16578-83, 2008. [Epub ahead of print].

  51. Reddy GR, Kuo CC, Tan UK, Coumar MS, Chang CY, Chiang YM, Lai MC, Wu SY, Chang JY, Liu JP and Hsieh HP. Synthesis and structure-activity relationships of 2-amino- and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents. J Med Chem. 2008 25; 51(24): 8163-8167.

  52. Chang KY, Chang JY, Chao J and Yen Y. Modern staging and utility of PET imaging in esophageal cancer management. J Natl Compr Canc Netw. 2008 Oct; 6(9):862-9.

  53. Juang SH, Lung CC, Hsu PF, Hseu KS, Li YC, Hong PC, Shiah HS, Kuo CC, Huang CW, Wang YC, Huang LY, Chen TS , Fong Chen SF, Fu KC , HL Hsu, Lin MJ, Chang CJ, Chou KM, and Chang JY*. D-501036, a Novel Selenophene-based Triheterocycle Derivative, Exhibits Potent in vitro and in vivo Anti-tumoral Activity Which Involves DNA damage and ATM activation. Molecular Cancer Therapeutics 6: 193-202, 2007 (NSC 94-2752-B-400-001-PAE).

  54. Shiah HS, Lee WH, Juang SH, Chang CJ, Chou KM and Chang JY*. Mitochondria-mediated and p53-associated apoptosis induced in human cancer cells by a novel selenophene derivative, D-501036. Biochemical Pharmacology 73(5): 610-619, 2007(NSC 94-2752-B-400-001-PAE).

  55. Chang WSW, Wu HR, Yeh CT, Wu CW and Chang JY. Lysosomal cysteine proteinase cathepsin S as potential target for anti-cancer therapy J. Cancer Mole. 3(1): 5-14, 2007.

  56. Chang WSW*, Chou RH, Wu CW and Chang JY* Human tissue kallikreins as diagnostic biomarkers and as targets for anticancer therapy. Experts Opinion on Therapeutic Patents 17(10): 1227-1240, 2007 (Invited review).

  57. Chien SC, Chang JY, Kuo CC, Hsieh CC, Yang NS and Kuo YS. Two novel skeleton compounds, chamaecypanone C and obtunorligan A, from the heartwood of Chaelaecyparis obtuse var.formosana. Tetrahedron Letters. 48(6); 1567-1569, 2007.

  58. Chen CC, Chen LT, Tsou TC, Pan WY, Yeh SC, Tsai FY, Hsieh HP and Chang JY*. Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. British Journal of Cancer 97(3): 334-344, 2007 (NSC 95-2752-B-400-001-PAE).

  59. Liou JP, Wu CY, Chang CY, Chen CM, Kuo CC and Chang JY*. 4- and 5- aroylindoles as novel classes of potent antitubulin agents. J Med Chem 50:4548-4552, 2007 (NSC 95-2752-B-400-001-PAE; NSC 95-2320-B-038-008).

  60. Kuo CC, Liu JF, Shiah HS, Ma, LC and Chang JY*. Tamoxifen accelerates proteosomal degradation of O6-methylguanine DNA methyltransferase in human cancer cells. International Journal of Cancer, 121(10):2293-300, 2007 Jun 27; [Epub ahead of print] (NSC 95-2752-B-400-001-PAE).

  61. Liou JP, Hsu KS, Kuo CC, Chang CY and Chang JY*. A novel oral indoline-sulfonamide agent, J30, exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule. JPET, Oct;323(1):398-405, 2007 Jul 27; [Epub ahead of print] (NSC 95-2752-B-400-001-PAE).

  62. Kuo CC, Liu JF and Chang JY*. DNA repair enzyme,O6-methylguanine methyltransferase, modulates the cytotoxicity of CPT-derived topoisomerase I inhibitors. Journal of Pharmacology and Experimental Therapeutics 316(2): 946-954, 2006 (NSC 94-2752-B-400-001-PAE).

  63. Shiah HS, Chen LT, Chao Y, Yao TJ, Huang JD, Chang JY, Chen PJ, Chuang TR, Chin YH, Jacqueline Whang-Peng, Liu TW. Phase I and Pharmacokinetic Study of Oral Thalidomide in Advanced Hepatocellular Carcinoma. Cancer Chemotherapy and Pharmacology 21(3): 531-6, 2006.

  64. Shiah HS, Chen AL, Hsu C, Hsu CH, Liu TW, Chang JY, Jan CM, Chao Y, Yu WL, Chuang TR, Whang P and Chen LT. Phase I-II study of gemcitabine and high dose 5-FU and leucovorin in advanced pancreatic cancer. J Gastroenterology and Hepatology, 21(3): 531-6, 2006.

  65. Ch'ang HJ, Wang CC, Cheng AL, Hsu C, Lu YS, Chang MC, Lin JT, Wang HP, Liu TW, Chang JY, Whang-Peng J and Chen LT. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-hr infusion of 5-fluorouracil/leucovorin for advanced pancreatic cancer. J Gastroenterology and Hepatology, 21(5): 874-9, 2006.

  66. Chen YL#, Lin SZ#, Chang JY#, Cheng YC, Tsai NM, Chang WL and Harn HJ. A novel potential anticancer agent of usochaihulactone on human lung cancer A549 in vitro and in vivo study. Biochemical Pharmacology 28: 72(3): 308-319, 2006 (#contributed equally).

  67. Liou JP, Mahindroo N, Kuo, FM, Lee SWH, Yeh TK, Tan UK, Kuo CC, Chang YW, Lu PH, Tung YS, Lin KT, Chang JY* and Hsieh HP*. SAR Studies of 3-Aroylindoles as Potent Antimitotic Agents to Improve the Physicochemical Properties. ChemMedChem, 1: 1106-1118, 2006 Sep 1 (NSC 94-2113M-400-001).

  68. Chang JY, Yang MF, Chang CY, Chen CM, Kuo CC and Liou JP*. 2-amino and 2'-aminocombrestatins as potent antitubulin agents. J Med Chem 49: 6412-6415, 2006 (NSC 95-2752-B-400-001-PAE; NSC 94-2323-B-038-005).

  69. Bacherikov VA, Tsai TJ, Chang JY, Chou TC, Leu RZ and Su TS. Synthesis of new camptothecin analogues in E-L lactone ring replaced with α, β-cyclohexenone. Eur J Org Chem 4490-4449, 2006.

  70. Chang JY, Hsieh HP, Chang CY, Hsu KS, Chiang YF, Chen CM, Kuo CC and Liou JP*. 7-Aroyl-aminoidoline-1-sulfonamides as a novel class of antitubulin agents. J Med Chem 49:6656-6659, 2006 (NSC 95-2752-B-400-001-PAE; NSC 95-2320-B-038-008). 
    Tse SK, Chang JY, Su WL, Chow SC, Hsiung C and Lu Q. Statistical Quality Control Process for Traditional Chinese Medicine. J Biopharm Stat. 2006;16(6):861-74.

  71. Hsieh CL, Tseng MH, Shao YY, Chang JY, Kuo CC, Chang CY and Kuo YH. C35 terpenoids from the bark of Calocedrus macrolepis var. formosana with cytotoxic activity against human cancer cell line. J Nat Prod 27;69(11):1611-1613, 2006.

  72. Mahindroo N, Liou JP, Chang JY*, Hsieh HP* Antitubulin agents for treatment of cancer- A medicinal chemistry update. Experts Opinion on Therapeutic Patents (Invited review) 16(5): 643-691, 2006 SCI:1.488.

  73. Chang JY*. Discovery of novel microtubule inhibitors as potential anticancer agent. Journal of Chinese Cancer Society (review), 21 (2): 1-9, 2005.

  74. Chang CI, Chang JY, Kuo CC, Pan WY and Kuo YH. Four New 6-Nor-5(6－>7)abeoabietane Type Diterpenes and Antitumoral Cytotoxic Diterpene Constituents from the Bark of Taiwania cryptomerioides. Planta Medica, 71(1): 72-76, 2005.

  75. Chiang YM, Chang JY, Kuo CC, Chang CY and Kuo YH. Cytotoxic triterpines from the aerial roots of Ficus Mircocarpa. Phycochemistry, 66 (4): 495-501, 2005.

  76. Chen CC, Chang JY, Liu KJ, Chan CH, Ho JH, Lee SC, and Chen LT. Hepatocellular carcinoma associated with acquired von Willebrand disease and extreme thrombocytosis. Annals of Oncology (Letter), 16(6), 988-9, 2005.

  77. Chan CH, Liu TW, Chen LT, Chang JY and Whang-Peng J. Long term complete remission of metastatic gastric cancer after weekly docetaxel. 24-hour infusion of high dose 5-FU and cisplatin. J Gastroenterology and Hepatology (Letter), 1470-1, 2005.

  78. Chen LT, Liu TW, Chang JY, Chao Y, Cheng, AL, Hsu C, Liu JM, Chuang TR, Chin YH, Wu CY, and Whang-Peng J. Clinical Significance of alpha-fetoprotein Response in Thalidomide-treated Advanced Hepatocellular Carcinoma. Alimentary Pharmacology and Therapeutics 22 (3): 217-226, 2005.

  79. Wang CC, Chang JY, Liu TW, Lin JY, Hsu CH, Yang CH, Yu YJ and Hong RL. Phase II study of gemcitabine/vinorelbine (GV) in the treatment of cisplatin-resistant nasopharyngeal carcinoma (NPC)—Head Neck, 28(1) 74-80, 2005.

  80. Bacherikov VA, Chang JY, Lin YW, Chen CH, Pan WY, Dong H, Lee RZ, Chou TC, and Su TL. Synthesis and antitumor activity of 5-(9-acrydinylamino)anisitine derivatives. Bioorganic and Med. Chem. 13: 6513-6520, 2005.

  81. Shiah HS, Liu TW, Chen LT, Chang JY. Liu JM, Chuang TR, Lee WS and Wnang-Peng J. Pulmonary embolism after transcatheter arterial chemoembolizaton Eur. J Cancer Care 14(5): 440-2, 2005.

  82. Chang JY*, Chang CY, Kuo CC, Chen LT, Wein YS and Kuo YH. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Dansen), with antimitotic activity in multidrug-sensitive and –resistant human tumor cells. Molecular Pharmacology 65(1): 77-84, 2004.

  83. Chang Chi-I, Kuo CC, Chang JY and Kuo YH. Three new oleanane-type triterpenes from Ludwigia octovalvis with cytotoxic activity against human cancer cells. J. Nat. Prod. 67, 91-93, 2004.

  84. Liou JP#, Chang JY#, Chang CW, Liu YC, Chang CY and Hsieh HP. Synthesis and structure-activity relationship of 3-aminobenzophenones as antimitotic agents. J Med. Chemistry, 2897-2905, 2004. (#contribute equally).

  85. Juang SH, Pan WY, Kuo CC, Liou JP, Chen LT, Hsieh HP and Chang JY*. A novel bis-benzylidenecyclopentanone derivative, BPR0Y007, inducing a rapid caspase activation involving upregulation of Fas (CD95/APO-1) and wild-type p53 in human oral epidermoid carcinoma cells. Biochemical Pharmacology. 68(2): 293-303, 2004 (corresponding author).

  86. Chao Y, Yeh KH, Chang CJ, Chen LT, Chao TY, Wu MF, Chang CS, Chang JY, Chung CY, Kao WY, Hsieh RK and Cheng AL. Phase II study of weekly oxaliplatin and 24-hour infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. British Journal of Cancer, 91(3): 453-8, 2004.

  87. Kuo, CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT and Chang JY*. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Research, 64: 4621-4628, 2004.

  88. Liou JP, Chang YL, Kuo FM, Chang CW, Tseng HY, Wang CC, Yang YN, Chang JY, Lee SJ, Hsieh HP. Concise Synthesis and Structure-Activity Relationships of Combretastatin A-4 Analogues, 1-Aroylindoles and 3-Aroylindoles, as Novel Classes of Potent Antitubulin Agents. J Med. Chem. 47, 4247-4257, 2004.

  89. Chang JY, Ka WS, Chao TY, Liu TW, Chuang TR and Chen LT. Treatment of hepatocellular carcinoma with intra-atrial tumor thrombi- a report of three thalidomide-responsive cases and literature review. Oncology 67: 320-326, 2004.

  90. Chang JY*, Hsieh HP, Pan WY, Liou JP, Bey SJ, Chen LT, Liu JF and Song JS, Dual Inhibition of Topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent. Biochemical Pharmacology 65(12): 2009-2019, 2003.

  91. Chang JY, Lin CF, Pan WY, Bacherikov V, Chou TC, Chen CH, Dong H, Cheng SY, Tsai TJ, Lin YW, Chen KT, Chen LT and Su TL. New analogues of AHMA as a potential antitumor agents: synthesis and biological activity. Bioorganic and Medicinal Chemistry 11: 4959-4969, 2003.

  92. Liu JM, Chen LT, Chao Y, Wu CW, Wu HW, Lee KD, Chang JY, Whang-peng J. Phase II and pharmacokinetic study of GL331 in refractory gastric cancer patients. Cancer Chemo and Pharmacol. 49: 425-428, 2002.

  93. Chen LT, Liu TW, Wu Cw, Chung TR, Shiah HS, Jan CM, Liu JM, Whang-Peng J and Chang JY* A Phase I Study of Weekly Docetaxel, Cisplatin Plus 24-Hour Infusion of High Dose Fluorouracil and Leucovorin in Patients with Advanced Gastric Cancer. Oncology, 63(3): 239-47, 2002.

  94. Chang JY*, Liu JF, Jung SH, Liu TW and Chen LT. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Cancer Res. 62: 3716-3721, 2002.

  95. Lee KD, Liu TW, Wu CW, Liu JM, Chung TR, Chang JY, Whang-Peng J and Chen LT. Non-surgical treatment for afferent loop syndrome in recurrent gastric cancer complicated by peritoneal carcinomatosis-Percutaneous transhepatic duodenal drainage followed by 24-hour infusion of high-dose fluorouracil and leucovorin. Annals of Oncology 13: 1151-1155, 2002.

  96. Rastogi K#, Chang JY#, Pan WY, Chen CH, Chou TC, Li-Tzong Chen, and Su TL . Antitumor AHMA Linked to DNA Minor Groove Binding Agents: Synthesis and Biological Evaluation. J Med Chem., 26: 45(20): 4485-93, 2002 (#contributed equally).

  97. Kuo CC, Chaing W, Liu GP, Chen YL, Chang JY, Lee CK, Lo JM, Huang SL, Shih MC and Kuo YH. 2,2'-diphenyl-1-picrylhydrazyl radical-scavenging active components from Adlay (Coix lachryma-jobi L. var. ma-yuen Stapf) Hulls. J Agric. Food Chem., 9: 50(21): 5850-5855, 2002.

  98. Hsieh HP, Liou JP, Lin YT, Marhindroo N, Chang JY, Yang YN, Chen SS, Tan UK, Chang CW, Chen TW, Lin CH, Chang YY and Wang CC. X-ray crystallographic and molecular modeling studies of benzophenone derivatives- the potential antimitotic agents. Bioorganic Medicinal Chemistry Letter, 12: 101-105, 2002.

  99. 張俊彥* 與第一型拓樸脢有關的抗癌藥物的新進展。國防醫學，30(2): 124-128, 2000.

  100. Chang JY, Guo X, Chen HX, Wang HK, Bastow KF, Zhu XK, Guan J, Lee KH, Cheng YC. Unique Biochemical, Cytotoxicity and Antitumor Activity of Camptothecin and 4B-amino-4'-O-demethyl Epipodophyllotoxin Conjugates, Biochemical Pharmacology. 59:497-508, 2000.

  101. 張俊彥*. 癌症治療的新進展。當代醫學雜誌 531-538,1999.

  102. Chen YC, Chang JY, Hsuch EJ, Wan HL, Chao TY. Acquired Hemophilia A: report of two cases. Chin Med J ( Taipei) 1998:538-544.

  103. Hwang WS, Hsiung CA, Ko WS, Wang CC, Chang JY, Lai GM, Hsieh RK, Tsao CJ, Chen LT, Law CK, Cheng AL, Fan SF, Tzeng CH, Chiou TJ, Whang-Peng J. Weekly CAF Chemotherapy for Advanced Breast Cancer Patients. Oncology 1997; 54: 293-297.

  104. Biedler DR, Chang JY, Zhou BS and Cheng YC. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res, 56: 345-353, 1996.

  105. Harn HJ, Ho LI, Liu CA, Lin FG, Lin JJ, Chang JY, Lee WH. Down regulation of bcl-2 by p53 in nasopharyngeal carcinoma and lack of detection of its specific t(14;18) chromosomal translocation in fixed tissues. Histopathology, 28(4): 317-23, 1996.

  106. Hsueh EJ, Hwang WS, Huang SH, Chao TY, Chang JY, Wang CC. Allogeneic Bone Marrow Transplantation for fourteen patients with severe Aplastic Anemia. China Med J (Taipei) 1996; 57: 247-253.

  107. Chao TY, Chow KC, Chang JY, Wang CC, Tsao TY, Harn HY, Chi KH Expression of Epstein-Barr Virus-Encoded RNAs as a marker for metastastic undifferentiated Nasopharyngeal Carcinoma. Cancer. July: 24-29 1996.

  108. Chen Li-Mien, Chao TY, Chiang JH, Chang JY, Hwang HS, Hseuh EJ, Wang CC. Examination of pericardial effusions by cytology and immunocytochemistry. Chin Med J (Taipei). 1996, 58 (4): 248-253.

  109. Yang Ching-Yue, Wong CS, Chang JY, Ho ST. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer patients. Can J Anaesth 43; 4: 379-83, 1996.

  110. Huang WH, Hseuh EJ, Huang SH, Chao TY, Wang CC and Chang JY. The effects of human granulocyte colony stimulating factor in allogenic bone marrow transplantation—TSGH experience. Journal of Medical Science 1996; 16: 349-354.

  111. Juan MT, Sheu LF, Chang JY* and Hwang WS. Primary Non-Hodgkin's lymphoma of the Mediastinum: A Clinicopathological Report of Six cases. Chin Med J (Taipei) 55: 325-330, 1995.

  112. Chao TY, Ting CS, Yeh MY, Chang JY, Wang CC and Chu TM. Effects of indomethacin on lymphokine-activated killer cell activitives in cancer patients. Tumor Biol 16: 230-242, 1995.

  113. Gao GW, Huang SH and Chang JY. Vertebral metastasis with spinal cord compression as an initial presentation of rare hepatocellular carcinoma. J Med Sci 16 (1): 68-73, 1995.

  114. Chao TY, Chang JY, Ju CY and Tsao TY. Diagnosis of disseminated candidiasis by fine needle aspiration of lymph node and by splenetic imprint in a patient with acute promyelocytic leukemia. Acta Haematol 1995; 94: 148-151.

  115. Huang SH, Ger LP, Hsueh EJ, Cheng LM and Chang JY. A randomized comparative trial of ordansetron versus metoclorpomide-based combination regimen in the prevention of cisplatin-induced emesis. J Med Sci 16(2):108-114, 1995.

  116. Chen YC, Chao TY, Hsueh EJ, Huang SH, Wang CC and Chang JY (corresponding author). A randomized study comparing tropisetron with combined metoclopromide and dexamethasone in the prevention of cisplatin-induced emesis. J Chniese Oncol. Soc. 11 (2):1-8, 1995.

  117. Harn HJ, Chang JY, Wang MW, Ho LI, Lee HS, Chiang JH, Lee WH. Epstein-Barr Virus-associated Gastric Adenocarcinoma in Taiwan. Human Path, 26 (3): 267-271, 1995.

  118. Harn HJ, Ho LH, Chang JY, Wu CW, Wang MW, Jiang SY, Lee HS, Lee WH. Differentiation expression of human metastasis adhesion molecule CD44V I Chinese stomach carcinoma. Cancer 75 (5): 1065-1071, 1995.

  119. Yu FC, Chang JY*, Hwang SH, Lee HS and Hwang WS. Kappa light chain multiple myeloma with myelomatous pleural effusion-a case report and review of literature. J Med Sci 15 (1): 49-56, 1994.

  120. Wang ZQ, Shen YC, Chen HX, Chang JY, Guo X, Cheng YC and Lee KH. Antitumor agnets 126. Novel 4B-substituted anilino derivatives of 3'4'-O'O' didemethylpodophyllotoxin as potent inhibitors of human DNA topoisomerase Ⅱ. Pharmaceutical Res. 10 (3): 343-350, 1993.

  121. Huang SH, Chang JY, Hsueh EJ, Sheu LF and Hwang WS. Lymphoblastic lymphoma in adult: an experience of 15 cases treated at the Tri-Service General Hospital. J Med Sci 14: 193-200, 1993.

  122. Chang JY and Hwang WS. Disseminated Intravascular Coagulation. Med Digest 6 (17): 504-508, 1993.

  123. Wang WS, Yang YF, Chang JS and Chang JY. A comparison study of regular metoclopramide with long-acting metoclorpamide for prophylaxis chemotherapy-induced delayed nausea and vomiting in patients with gynecological cancer. J Obstet and Gynecol ROC 32 (4): 1-5, 1993.

  124. Chang JY, Dethlefsen LY, Barley LR, Zhou BS and Cheng YC, Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem Pharmacol 43 (11): 2443-2452, 1992.

  125. Chang JY, Han FS, Liu SY, Wang ZQ, Lee KH and Cheng YC. Effect of 4B-arylamino derivatives of 4'-o-demethylepipodophyllotoxin on human DNA topoisomeraseⅡ, tubulin polymerization, KB cells and their resistant variants. Cancer Res. 51: 1755-1759, 1991.

  126. Emily O, Ngo, Sun TP, Chang JY, Wang CC, Chi KH, Cheng AL and Nutter LM, Menadione-induced DNA damage in a human tumor cell line. Biochem Pharmacol 42 (10): 1961-1968, 1991.

  127. Chang JY, Chen LM, Tseng HW and Hwang WS. Granulocytic sarcoma with massive skin involvement. Hemal Soc Aut. 71-77, 1991.

  128. Lee KH, Beers SA, Mori M, Wang ZQ, Li Li, Liu SY, Chang JY, Han FS and Cheng YC. Antitumor agents 111. New 4'-hydroxylated and 4'-halogenated anilino derivatives of 4'-demethylepipodophyllotoxin as potent inhibitor of human DNA topoisomerase Ⅱ. J Med Chem 33 (5): 1365-1368, 1990.

  129. Ko WS, Chen A, Yu KP, Chang JY, Hwang WS and Lee WC, Stimultaneous Occurrence of malignant lymphoma and hepatocellular carcinoma. Hemal Soc Aut 15-18, 1990.

  130. Wang ZQ, Kuo YH, Schnur D, Bwoen JP, Liu SY, Han Fs, Chang JY, Cheng YC and Lee KH, Antitumor agents 113. New 4B-arylamino derivatives of 4'-o-demethylepipodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomeraseⅡ. J Med Chem 33 (9): 2661-2666, 1990.

  131. Cheng AL, Chen YC, Wang CW, Tien HF, Chang JY, Hwang WS, Su WC and Liu CH. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades-Should peripheral T-cell lymphoma be considered separately? J Clin Oncol 7 (6): 725-731, 1989.

  132. Chang JY, Hwang WS, Yu KP and Lee WC, Combination chemotherapy of Non-Hodgkin’s Lymphoma with CHOP. J Med Sci 8 (4) , 1988.

  133. Hwang WH, Lee EC and Chang JY. Epirubicin in combination chemotherapy for hematological malignancy. J Med Sci 8 (1): 1987.

  134. Lin JS, Yu KP, Hwang WS, Lee WC and Chang JY. Chronic myelocytic leukemia -- Clinical analysis of 52 cases. Chin Med J 36:372-378, 1985.

(B) Manuscript in Submission and Revision

  1. Chen, K.-L., Chang, W.-S. W., Lin, C.-C., Cheung, C.-H.A., Kuo, C.-P., Kuo, C.-C., Chang, Y.-H., Liu, K.-J., Chang, J.-Y.* Targeting cathepsin S induces tumor cell autophagy via the EGFR-ERK signaling pathway. Cancer Letters 317:89-98, 2012

(C) Conference Abstracts

  1. Chen, H.-H., Huang, Y.-W., Cheng, Y.-T., Lai, W.-Y., Chang, J.-Y., Kuo, C.-C.* Activation of NRF2/ABCC1 axis confers resistance to topoisomerase II poisons in human oral malignancies. American Association for Cancer Research 102nd Annual Meeting. Abstract #1528. Orlando (USA). April 2~6, 2011.

  2. Kuo, C.-C., Chang, J.-Y., Cheng, Y.-T., Wan, H.-J., Lee, W.-S., Chen, H.-H., Chang, C.-Y., Pan, W.-Y., Chen, L.-T., Shiah, H-S.* 1701/10 - Activation of Akt/FoxO axis confers resistance to cisplatin in human nasopharyngeal carcinomas. American Association for Cancer Research 102nd Annual Meeting. Abstract #1701. Orlando (USA). April 2~6, 2011.

  3. Chen, K.-L, Chang, W.-S.W., Lin, C.-C., Cheung, C.H.A., Kuo, C.-P., Kuo, C.-C., Chang, Y.-H., Liu, K.-J., Chang, J.-Y.*Targeting cathepsin S induces tumor cell autophagy via the EGFR-ERK signaling pathway. American Association for Cancer Research 102nd Annual Meeting. Abstract #2864. Orlando (USA). April 2~6, 2011.

  4. Cheng, Y.-C., Liou, J.-P., Lai, W.-Y., Chang, C.-Y., Pan, W.-Y., Kuo, C.-C., Chang, J.-Y.* MPT0B098, a novel microtubule inhibitor, displays potent anti-angiogenic activity via destabilizing hypoxia-inducible factor-1alpha mRNA. American Association for Cancer Research 102nd Annual Meeting. Abstract #4461. Orlando (USA). April 2~6, 2011.

  5. Chen, S.-H., Yang, Y.-N., Li, C.-F., Huang, H.-Y., Liu, J.-F., Kuo, C.-C.*, Chang, J.-Y.* DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates therapeutic efficacy of platinum drugs with radiation and its clinical significance. The 16th Joint Congress of Oncology Societies of Taiwan. Abstract #C-7-32. Taipei (Taiwan). April 30 ~ May 1, 2011. (Award of the Best Research Project)

  6. Cheung, C.H.A., Wu, S.-Y., Chang, C.-Y., Hsieh, H.-P., Chang, J.-Y. Class I β-tubulin mutations induce resistance tomicrotubule destabilizer through stabilization of the microtubule networks.AACR 101st meeting. Abstract No. 2555. 2010.

  7. Cheung, C.H.A., Chen, H.-H., Cheng, L.-T., Lyu, K.W., Kanwar, J.R., Chang, J.-Y. Targeting Hsp90 with small molecule inhibitors induces the overexpression of the anti-apoptotic molecule, survivin, in human cancer cells. AACR 101st meeting. Abstract No. 4447. 2010.

  8. Chang, K.Y., Chang, J.-Y. Novel PI3K/mTOR dual inhibitor, NVP-BGT226, displays potent inhibitory activity against human head and neck cancer cell growth in vitro and in vivo. AACR 101st meeting. Abstract No. 4471., 2010.

  9. He, F.-Y., Chang, J.-Y., Kuo, C.-C., Pan, W.-Y., Chen, L.-T., Weng, W.-H. microRNA expression patterns associated with resistance to platinum-based chemotherapy in human cancer cell lines. AACR 101st meeting. Abstract No. 2045, 2010.

  10. Chang, J.-Y. Cathepsin S: a potential target for anticancer drug discovery. Invited speaker at Lecture 26. The 15th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-12. Taipei (Taiwan). May 1~2, 2010.

  11. Yang, Y.-N., Pan, W.-Y., Yeh, S.-C., Tsou, T.-C., Chen, L.-T., Chang, J.-Y. Enhancement of Non-homologous End Joining DNA Repair Capacity Confers Cancer Cells Resistant to Novel Selenophene Compound D-501036. The 15th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-13. Taipei (Taiwan). May 1~2, 2010.

  12. Cheung, C.H.A., Chen, H.-H., Cheng, L.-T., Lyu, K.W., Kanwar, J.R., Chang, J.-Y. Targeting Hsp90 with small molecule inhibitors induces the overexpression of the anti-apoptotic molecule, survivin, in human cancer cells. The 15th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-25. Taipei (Taiwan). May 1~2, 2010.

  13. Cheung, C.H.A., Wu, S.-Y., Chang, C.-Y., Hsieh, H.P. Chang, J.-Y. Class I β-tubulin mutations induce resistance to microtubule destabilizer through stabilization of the microtubule networks. The 15th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-26. Taipei (Taiwan). May 1~2, 2010.

  14. Kuo, C.-C., Liu, T.-W., Chen, L.-T., Shiah, H.-S., Pan, W.-Y., Liu, J.-F., Cheng, Y.-T., Chang, J.-Y. Synergistic augmentation of arsenic trioxide–induced cytotoxicity by BCNU through reactive oxygen species-related autophagic pathway in human solid tumors. The 15th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-14. Taipei (Taiwan). May 1~2, 2010.

  15. Chen, H.-H., Cheng, Y.-T., Lai, W.-Y., Chang, J.-Y., Kuo, C.-C. Development of Etoposide-driven Drug Resistance through NRF2/ABCC1 Axis in Human Oral Malignancies. The 15th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-16. Taipei (Taiwan). May 1~2, 2010.

  16. Cheng, Y.-C., Lai,W.-Y., Chang, C.-Y., Pan, W.-Y., Liou, J.-P., Kuo, C.-C., Chang, J.-Y. MPT0B098, a novel microtubule-destabilizing agent, inhibits tumor growth by an antiangiogenic mechanism linked to the targeting of PI3K/AKT/HIF-1a/VEGF signaling in non-small cell lung cancer. The 15th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-12. Taipei (Taiwan). May 1~2, 2010.

  17. Cheng, Y.-T., Chen, H.-H., Hsiao, J.-R., Chen, L.-T., Chang, J-Y., Kuo, C.-C.* Combined modalities of resistance in a cisplatin-driven human betel-associated oral squamous cell carcinoma. 35th ESMO Congress. Milan (Italy). October 8 ~12, 2010.

  18. Kuo, C.-C., Chang, J.-Y., Pan, W.-Y., Liou, J.-Y., Chen, L.-T. Activation of Nrf2/AKR1C axis determines chemoresistance in gastric and pancreatic carcinomas. Asia-Pacific Congress on Pancreas and Biliary Tract Cancer in Conjunction with the 14th Annual Meeting of Taiwan Cooperative Oncology Group & 2010 International Conference on Translational Cancer Research. Taipei (Taiwan). November 20 ~ 21, 2010.

  19. Cheng, Y.-C., Lai, W.-Y., Chang, C.-Y., Pan, W.-Y., Liou, J.-P., Kuo, C.-C., Chang, J.-Y.. MPT0B098, a novel microtubule-destabilizing agent, displays anti-angiogenic potential via AKT/p70S6K/HIF-1 alpah/VEGF signaling in lung cancers. Proceeding of APCC, #P-50, 2009.( Young Investigators Award)

  20. Chang, C.-Y., Lung, C.-C., Kuo, Y.-H., Kuo, C.-C., Hsu, K.-S., Lu, K.-H., Lin, C.-H., Chang, J.-Y.YS-5, A novel neolignan induces apoptosis cell death via activated spindle assembly checkpoint in human cancer cells. Proceeding of APCC, #P-74, 2009.

  21. Chen LT, Shiah HS, Chen C, Lin Y, Lin P, Su W and Chang JY. Randomized, phase I and PK study of RAD001, a mTOR inhibitor, in patients with advanced HCC. ASCO GI meeting. 2009.

  22. Cheung, C.-H. A., Kuo, C.-C., Chen, H.-H., Chang, C.-Y., Coumar, M.S. Hsieh, H.-P., Chang, J.-Y. Down-regulation of survivin enhances sensitivity to BPR0L075 in human cancer cells via caspase-independent mechanisms. The 14th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-21. Taipei (Taiwan). May 2~3, 2009.

  23. Liu, K.-J., Kuo, C.-C., Hong, Y.-M., Yang, Lai, W.-Y., Lin, C.-C., Chang, M. D.-T., Lyu, P.-C., Uang, B.-J., Chang, J.-Y. A novel a-ketone amide compound CCL-ymc-7K with inhibitory activity on cathepsin S displays anti-angiogenesis potential. The 14th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-23. Taipei (Taiwan). May 2~3, 2009.

  24. Chen, J.-J., Lin, C.-C., Wang, X.-J., Lin, S.-J., Chang, D.-T., Lin, S.-C., Chiang, G.-H., Lee, P.-Y., Chang, W.-S., Kuo, C.-C., Liu, K.-J., Chang, J.-Y. Synthesis of a-ketone amides as cathepsin S inhibitors. The 14th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-39. Taipei (Taiwan). May 2~3, 2009.

  25. Lu, H.-J., Uang, B.-J., Liu, K.-J., Kuo, C.-C., Chang, Chang, W.-S., Chang, J.-Y. Discovery of potent inhibitors for cathepain S. The 14th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-42. Taipei (Taiwan). May 2~3, 2009.

  26. Liu, K.-J., Chang, W.-S., Kuo, C.-C., Hong, Y.-M., Yang, Y.-N., Liu, H.-J., Uang, B.-J., Chang, J.-Y. HJL-kpw-2py-03, a novel p38 MAPK inhibitor derivative with potent anti-angiogenic and anti-metastatic activities against human malignancies. The 14th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-45. Taipei (Taiwan). May 2~3, 2009.

  27. Chiang, G.-H., Lin, S.-C., Lee, P.-Y., Chen, J.-J., Lin, C.-C., Kuo, C.-C., Liu, K.-J., Chang, J.-Y., Chang, M. D.-T., Uang, B.-J., Chang, W.-S. CCL-ymc-7K, a newly synthesized a-ketone amide compound, serves as a direct inhibitor of Cathepsin S protease to reduce tumor cell migration and invasion. The 14th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-59. Taipei (Taiwan). May 2~3, 2009.

  28. Lin, S.-C., Chiang, G.-H., Lee, P.-Y., Chen, J.-J., Lin, C.-C., Kuo, C.-C., Liu, K.-J., Chang, J.-Y., Chang, M. D.-T., Uang, B.-J., Chang, W.-S. Study of the anti-migratory and anti-invasive effects of newly synthesized inhibitors of cancer-related cathepsin S protease. The 14th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-62. Taipei (Taiwan). May 2~3, 2009.

  29. Cheung, C.-H.A., Chang, C.-Y., Hsieh, H.-P., Chang, J.-Y. Down-regulation of survivin enhances sensitivity to BPR0L075 in human cancer cells via caspase-independent mechanisms. American Association for Cancer Research 100th Annual Meeting. Abstract # 5542. Denver (USA). April 18~22, 2009.

  30. Hsieh, C.-C., Kuo, Y.-H., Kuo, C.-C., Chang, C.-Y., Chien, S.-C., Chang, J.-Y. Chamacypanone C, a novel skeleton microtubule inhibitor with antimitotic activity in human tumor cells. The 13th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-18. Taipei (Taiwan). May 3~4, 2008. (Award of the Best Research Project)

  31. Kao, Y.-H., Hsieh, H.-P., Kumar, S., Pan, W.-Y., Kuo, C.-C., Hsu, K.-S., Chang, C.-Y., Liu, J.-F., Chuang, S.-E., Chang, J.-Y. A novel peroxisome proliferators-activated receptor y a/r agonist, BPR1H0101, inhibits DNA topoisomerase II catalytic activity in human cancer cells. The 13th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-19. Taipei (Taiwan). May 3~4, 2008. (Award of the Best Research Project)

  32. Yeh TK, Li CM, Chen CP, Huang CL, Wang HS, Shen CJ, Chang CY, Chang, CM, Chao YS, Lin CT, Chang JY, and Chen CT. Comparative Antitumor Activities and Pharmacokinetics of Silatecans DB-67 and DB-91. Joint Meeting of Chinese Oncology Society, 2008.

  33. Hsieh CC, Kuo YS, Kuo CC, Chang CY, Chien SC, and Chang JY. Chamacypanone C, a Novel Skeleton Microtubule Inhibitor with Antimitotic Activity in Human Tumor Cells. Joint Meeting of Chinese Oncology Society, 2008.

  34. Chen LT, Chang TC, Cheng AL, Yang CH, Shiah HS, Chang JY, Yeh CG. Phase I study of liposome encapsulated irinotecan (PEP02) in advanced solid tumor patients. ASCO proceeding, # 2565, 2008.

  35. Chang JY and Liu JP. A novel oral indoline-sulfonamide derivative, J30, exhibits potent activity against human cancer cells both in in vitro and in vivo through disruption of microtubule. 6th AFMC International Medicinal Chemistry Symposium, 2007 (invited speech).

  36. Reddy, G.R., Liou, J.-P., Chang, C.-Y., Kuo, C.-C., Chang, J.-Y., Hsieh, H.-P. Synthesis and structure-activity relationships of aroyl naphthophenones as anti-tubulin agents. Annual Chinese Chemical Society & ICCT 2007 Joint Conference. Hsinchu (Taiwan). Dec 12~16, 2007.

  37. Kuo, C.-C., Liu, J.-F., Shiah, H.-S., Ma, L.-C., Chang, J.-Y. Tamoxifen accelerates ubiquitin-dependent proteasomal degradation of O6 methylguanine DNA methyltransferase in human cancer cells. The 12th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-1. Taipei (Taiwan). May 6~7, 2007. (Award of the Best Research Project)

  38. Kao, Y.-H., Hsieh, H.-P., Kumar, S., Pan, W.-Y., Kuo, C.-C., Hsu, K.-S., Chang, C.-Y., Liu, J.-F., Chuang, S.-E., Chang, J.-Y. BPR1H0101, a novel synthetic peroxisome proliferators-activated receptor y a /r (PPAR a /r) agonist, inhibits topoisomerase II catalytic activity. The 12th Joint Congress of Oncology Societies of Taiwan. Abstract #A-I-2. Taipei (Taiwan). May 6~7, 2007.

  39. Chen LT, Chen CC, Tsou TC, Pan WY, Kuo CC, Liu JF, Yeh SC, Tsai FY, Hsieh HP, Chang JY*. Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-FU. Proceeding of EORTC-NCI-AACR, 59, 2006.

  40. Lung CC ,Juang SH, Hsu PC, Hseu KS, Shiah HS, Li YC, Kuo CC, Chang CJ, and Chang JY*. D-501036, a Novel Selenophene-based Triheterocycle Derivative, Exhibits Potent in vitro and in vivo Anti-tumoral Activity Which Involves DNA damage and ATM activation. Proceeding of EORTC-NCI-AACR, 92, 2006.

  41. Kuo CC, Liu JF, and Chang JY*. Tamoxifen accelerates proteosomal degradation of O6-methylguanine DNA methytransferase in human cancer cells. Proceeding of EORTC-NCI-AACR, 155, 2006.

  42. Lung CC, Chang CY, Hsu KS and Chang JY. ATP-independent transporter responsible for the resistance of topoisomerase I inhibitors in a KB-Vin 10 cells. Proceeding of AACR, 2005.

  43. Chang JY, Liu TW, Pan WY, Liu JF, Kuo CC, Yang YN, Chen LT and Chen SA. Synergistc cytotoxicity of arsenic trioxide and BCNU in human cancer cells and its mechanism of interaction. Joint meeting of Chinese Oncology Society, 2005.

  44. Chang JY, Chen LT and Chang CY. DB67, a novel topoisomerase I inhibitor, synergize with cisplatin to induce protein-linked DNA breaks in human cancer cells. Joint Meeting of Chinese Oncology Society, 2005.

  45. Shiah HS, Lee WS, Juang SH, Chang CJ, Chang JY. Induction of cell death by a novel selenophene derivative, D-501036, in human cancer cells. Clinical Cancer Research 11(24) part 2, 9101s, 2005.

  46. Kuo CC, Hiesh HP, Pan WY, Liu JP, Chen LT, Chen CT and Chang JY. BPR0L075, a novel synthetic indole compound with antimitotic activity in multidrug-sensitive and –resistant cells, exerts effective antitumoral activity in vivo. Proceeding AACR 45:1254, 2004.

  47. Jung SH, Pan WY, Kuo CC, Liou JP, Chen LT, Hiesh HP and Chang JY. A novel bis-benzylidenecyclopentanone derivative, BPR0Y007, inducing a rapid caspase activation involving upregulation of Fas (CD95/APO-1) and wild-type p53 in human oral epidermoid carcinoma cells. Proceeding AACR, 45:1057, 2004.

  48. Lung CC, Kuo CC, Liu JF, J Whang-Peng and Chang JY. Transcriptional suppression of MGMT gene in CPT-resistant cells Proceeding AACR: 45:518, 2004.

  49. Chen T, Juang SH, Li Y, Huang C, Hsu P, Chen S, Chang JY, Hong P, Hsieh W, Chang C.Rapid activation of caspases involving microtubule stabilization and p53 upregulation by D501036, a novel selenophene derivative active against renal cancer cells. Proceeding of EORTC-NCI-AACR, 235, 2004.

  50. Wang CC, Hong RL, Hsu CH, Yang CH, Yu YC and Chang JY. A phase II trial of gemcitabine/vinorelbine combination in the treatment of platinum-resistant nasopharyngeal carcinoma. Proceeding ASCO, 2003.

  51. Kuo CC, Liu JF and Chang JY. O6-methylguanine methyltransferase plays a role in determining cytotoxicity of topoisomerase I inhibitors. Proceeding AACR, 2003.

  52. Kuo CC, Hsieh HP, Pan WY, Chen LT and Chang JY. BPR0L075, an indole analogue with antimitotic activity in multidrug-sensitive and –resistant human cancer cells. Chinese Oncology Society Annual meeting, 2003.

  53. Chang JY, Lin CF, Pan WY, Chou TC, Chen LT, and Su TL. Synthesis and Structure-Activity Relationships of New AHMA Derivatives as Topoisomerase II-mediated antitumor Agents. Chinese Oncology Society Annual meeting, 2003.

  54. Chao Y, Yeh KH, Chang CJ, Chen LT, Chao TY, Wu, MF, Chang CS, Chang JY, Chung CY, Kao WY, Hsieh RK, Chang AL. A phase II study of oxaliplatin and weekly 24-hour infusion of high dose 5-FU and leucovorin in the first line treatment of inoperable, locally advanced or recurrent/metastatic gastric cancers. Proceeding ASCO, 2002.

  55. Chang JY, Liu JF, Liu TW and Chen LT. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Cross-strait oncology meeting, 2002.

  56. Chang JY, Hsieh HP, pan WY and Liou JP. Dual actions of a new anticancer agent, BPR0Y007, on DNA topoisomerase I and tubulin. Proceeding AACR , 2002.

  57. Su TL, Rastogi K, Chang JY, Chou TH, Pan WY and Chen LT. AHMA derivatives linked to DNA minor groove binder as potential antitumor agents. Proceeding AACR, 2002.

Book：

  1. 吳秋文等主編: 胃癌的診斷與治療：胃癌之輔助化學治療。Pp 419-426

Patents:

  1. 芳香羰吲哚化合物 Hsieh HP, Liou JP, Chang JY, Chang CW December 1, 2009 – December 11, 2022 ROC TWI317634

  2. Indole Compounds Hsieh HP, Liou JP, Chang JY, Chang CW August 23, 2005 – December 12, 2022 USA US6933316

  3. 5-(9-Acridinylamino)-Toluidine Compounds Su TL, Chou TC and Chang JY Jan. 1, 2006 ~ Dec. 13, 2023 ROC ROC 1-246508

  4. Etoposide analogs Lee, K.H.; Zhou, X.M.; Wang, Z.Q.; Chang, J.Y.; Chen, H.X.; Cheng, Y.C.; Shen, Y.C.; Han, F.S.; Hu, H., Zhang, Y.L Jul. 26, 1994 ~ Jul. 26, 2011 USA US 5332811

  5. 5-(9-Acridinylamino)-Toluidine Compounds Su TL, Chou TC and Chang JY Jul. 30, 2003 ~ Jul. 29, 2023 USA US 6821983 B2

  6. Indoline-Sulfonamides Compounds Liou JP, Chang JY, Hsieh HP June 22, 2010 – August 31, 2027 USA US7741495

  7. Indoline-sulfonamides compounds Liou, J.P.; Chang, J.Y.; Hsieh, H.P June 4, 2009 – August 31, 2027 AU2007214336

  8. Anti-Tumor Compounds Hsieh HP, Tung YS, Liou JP, Chang JY, Chao, YS May 1, 2008 – December 27, 2025 ROC TWI296195

  9. Indoline-sulfonamides compounds Liou, J.P.; Chang, J.Y.; Hsieh, H.P May 13, 2009 – August 31, 2027 GB2441396

  10. Indoline-sulfonamides compounds Liou, J.P.; Chang, J.Y.; Hsieh, H.P May 28, 2010 – August 31, 2027 Japan JP 4521428

  11. Indole Compounds Hsieh HP, Liou JP, Chang JY, Chang CW May 5, 2009 – December 12, 2022 USA US7528165

  12. Indoline-sulfonamides compounds Liou, J.P.; Chang, J.Y.; Hsieh, H.P November 13, 2008 – August 31, 2027 NZ561060

  13. Anti-Tumor Compounds Hsieh HP, Tung YS, Liou JP, Chang JY, Chao, YS November 25, 2008 – December 15, 2025 USA US7456289

  14. Indoline-sulfonamides compounds Liou, J.P.; Chang, J.Y.; Hsieh, H.P October 1, 2009 – August 31, 2027 ROC TWI315304

  15. Cheng, C.T.; Chang, J.Y Sep. 27, 2002 ~ Sep. 26, 2022 ROC TW0228417B 
    Indoline-sulfonamides compounds Liou, J.P.; Chang, J.Y.; Hsieh, H.P September 4, 2009 – August 31, 2027 KR10-0916989

  16. Indole Compounds as inhibitors of tubulin polymerization for the treatment of angiogenesis-related disorders Hsieh HP, Liou JP, Chang JY, Chang CW 2010 Europe EP1506960

  17. Indole Compounds Hsieh, H.P.; Liou, J.P.; Chang, J.Y.; Chang, C. W December 15, 2009 – December 12, 2022 USA US7632955
 
　

　

 

其他

 

瀏覽數:
加到我的最愛
友善列印
登入成功